Gelatinous Transformation of Bone Marrow in Chronic Myeloid Leukemia during Treatment with Imatinib Mesylate: A Disease or a Drug Effect?

Publisher： Karger

E-ISSN： 1421-9662|119|2|104-107

ISSN： 0001-5792

Source： Acta Haematologica, Vol.119, Iss.2, 2008-03, pp. : 104-107

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Ph‐negative isolated myeloid sarcoma with NPM1 gene mutation in adolescent with Ph‐positive chronic myeloid leukemia in remission after treatment with allogeneic bone marrow transplantation and imatinib mesylate

By  

PEDIATRIC BLOOD & CANCER (ELECTRONIC), Vol. 62, Iss. 6, 2015-06 ,pp. : 1070-1071

John Wiley & Sons Inc

Access to resources Recommend Favorite

Long-Term Outcomes after Imatinib Mesylate Discontinuation in Chronic Myeloid Leukemia Patients with Undetectable Minimal Residual Disease

By  

Acta Haematologica, Vol. 135, Iss. 3, 2015-11 ,pp. : 133-139

Karger

Access to resources Recommend Favorite

The Importance of Body Surface Area at Baseline and during Treatment in Chronic Myeloid Leukemia Patients Treated with Imatinib

By  

Acta Haematologica, Vol. 134, Iss. 1, 2015-04 ,pp. : 57-58

Karger

Access to resources Recommend Favorite

Promyelocytic Crisis of Chronic Myelogenous Leukaemia during Imatinib Mesylate Treatment

By  

Acta Haematologica, Vol. 117, Iss. 4, 2006-12 ,pp. : 191-196

Karger

Access to resources Recommend Favorite

Apoptosis-Related Gene Expression Profile in Chronic Myeloid Leukemia Patients after Imatinib Mesylate and Dasatinib Therapy

By  

Acta Haematologica, Vol. 133, Iss. 4, 2015-02 ,pp. : 354-364

Karger

Access to resources Recommend Favorite